Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

China First to Approve Oral Drug to Stimulate Erythropoiesis

December 30, 2021

China's National Medical Products Administration approved the oral anemia drug roxadustat, well before regulators in the U.S. or Europe have issued decisions. The hypoxia-inducible factor prolyl-hydroxylase inhibitor mimics the body's response to high altitude and is a convenient alternative to injectable blood enhancers.

The decision was based on results from an open-label, phase III trial comparing roxadustat with epoetin alfa in patients with dialysis-dependent anemia who were previously treated with various erythropoiesis-stimulating agents. The approval clears its use in patients with anemia caused by chronic kidney disease who are on dialysis.

Source: Reuters, December 18, 2018.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals